Tripletail Wealth Management LLC Purchases Shares of 786 Eli Lilly and Company $LLY

by · The Cerbat Gem

Tripletail Wealth Management LLC acquired a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 786 shares of the company’s stock, valued at approximately $613,000. Eli Lilly and Company comprises 0.9% of Tripletail Wealth Management LLC’s portfolio, making the stock its 27th biggest position.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after acquiring an additional 81,587 shares during the period. Laurel Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank bought a new position in Eli Lilly and Company during the 2nd quarter worth approximately $8,827,714,000. Finally, Jennison Associates LLC increased its stake in Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after purchasing an additional 226,620 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.5%

NYSE:LLY opened at $995.63 on Tuesday. The company has a 50-day moving average price of $924.25 and a 200-day moving average price of $812.32. The stock has a market cap of $941.25 billion, a price-to-earnings ratio of 48.71, a P/E/G ratio of 1.12 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the previous year, the company earned $1.18 earnings per share. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LLY. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $886.00 to $1,104.00 in a research note on Monday, November 10th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, December 3rd. CICC Research raised their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Finally, Guggenheim reaffirmed a “buy” rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,087.32.

View Our Latest Report on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).